# GLP-1 Drugs After Age 80: A Matched Cohort of 11,464 Pairs With Diabetes

A matched diabetes cohort compared GLP-1 and DPP-4 inhibitor users aged 80 or older for cardiovascular, kidney and other outcomes.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/past-eighty-where-no-trial-goes
Updated: 2026-11-15
Published: 2026-09-17

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 Drugs After Age 80: A Matched Cohort of 11,464 Pairs With Diabetes

In 11,464 matched pairs aged 80 or older with type 2 diabetes, GLP-1 use was associated with lower mortality than DPP-4 inhibitor use.

Editorial profile: [Carla Medina](https://buythisglp.com/authors/carla-medina)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20263 min readUpdated November 2026

Mean age 81.6 · 11,464 matched pairs · death (any cause) · 0.82 · cardiovascular events · 0.86 · kidney events · 0.86 · hospitalization · 0.91 · heart failure · no significant difference · Hazard ratios from a matched cohort.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

Studies of [who receives GLP-1 treatment](https://buythisglp.com/research/who-the-price-filtered-out) examine access across age groups. This study instead compared health outcomes for people aged 80 and older who started one of two diabetes treatments [\[1\]](https://buythisglp.com/research/past-eighty-where-no-trial-goes#ref-1).

## What the study compared

Researchers matched 11,464 pairs of people with type 2 diabetes who started either a GLP-1 receptor agonist or a DPP-4 inhibitor. Follow-up extended up to five years [\[1\]](https://buythisglp.com/research/past-eighty-where-no-trial-goes#ref-1).

Death from any cause was recorded in 14.5% of GLP-1 users and 19.1% of DPP-4 users. The estimated hazard ratio was 0.82 (95% CI 0.77 to 0.88). The hazard ratios for major cardiovascular and major kidney events were each 0.86.

## How to read the safety findings

Research on [fractures in another GLP-1 cohort](https://buythisglp.com/research/half-the-fractures-two-in-a-thousand) examines a different population. This study found no statistically clear difference in fracture or heart failure hazards [\[1\]](https://buythisglp.com/research/past-eighty-where-no-trial-goes#ref-1).

Matching accounted for measured characteristics. Unmeasured factors, such as functional status or the reasons one treatment was chosen, could still affect the results. The study applies most directly to older adults starting treatment for type 2 diabetes.

## Frequently asked

How did mortality differ in this cohort?

The estimated mortality hazard was lower among GLP-1 users (hazard ratio 0.82). This observational comparison cannot establish cause.

Were heart failure and fractures less common?

The study found no statistically clear difference between the two groups for either outcome.

## Sources

1.  \[1\] Chen JC, Fang YW, Liu YF, Chen MT, Tsai MH (2026). GLP-1 Receptor Agonist Therapy and Cardiorenal Outcomes in Patients ≥ 80 Years Old With Type 2 Diabetes Journal of the American Geriatrics Society. [PMID 41132144](https://pmc.ncbi.nlm.nih.gov/articles/PMC12774297/)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
